HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siegel, J. A. Articles by Simon, W. E. Search for Related Content PubMed PubMed Citation Articles by Siegel, J. A. Articles by Simon, W. E.

Accurate Dose Calibrator Activity Measurement of ⁹⁰Y-Ibritumomab Tiuxetan

¹ Nuclear Physics Enterprises, Wellington, Florida
² National Institute of Standards and Technology, Gaithersburg, Maryland
³ Cardinal Health Nuclear Pharmacy Services, Woodland Hills, California
⁴ Capintec, Inc., Ramsey, New Jersey
⁵ Sun Nuclear Corp., Melbourne, Florida

ABSTRACT

This investigation examined the accuracy of dose calibrator activity measurement of the ß-emitting radiopharmaceutical ⁹⁰Y-ibritumomab tiuxetan. Methods: Five different facilities independently measured ⁹⁰Y in a 10-mL syringe geometry with 30 dose calibrator models from 3 different manufacturers. The activities ranged from 81.4 MBq (2.2 mCi) to 1,406 MBq (38 mCi) over the volume range of 3–9 mL. Results: The mean dial settings for ⁹⁰Y measurement were 375, 51 x 10, and 897 x 100 for Atomlab, CRC, and Mark V dose calibrators, respectively. The maximum volume dependence was 0.28%/mL. Conclusion: This study demonstrated that when measuring all volumes of ⁹⁰Y-ibritumomab tiuxetan activity prescriptions, only a single dial setting for a given manufacturer’s dose calibrator is required for accurate measurements. Volume corrections are not necessary. For best accuracy, an individually determined dial value should be used.

Key Words: ⁹⁰Y measurement • dose calibrator • ibritumomab tiuxetan

This article has been cited by other articles:

				R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]